Navigation Links
Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
Date:3/19/2012

GREENWOOD VILLAGE, Colo., March 19, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.

Conducted at St. Michael Hospital in Toronto Canada, the trial explored the safety and efficacy of twice-daily oral doses of Optina™, to reduce macular edema as determined by OCT (optical coherence tomography). OCT is a measure of the thickness of the macula, the area of the retina responsible for color and sharp vision. Macular edema, or swelling of that part of the retina, is a common consequence of diabetes and is the first step in the development of diabetic blindness.

According to Dr. Vaughan Clift, Chief Regulatory Officer of Ampio, "A preliminary assessment, of the primary end point (OCT) indicates a beneficial and consistent effect with the ultra-low dose of Optina™ at 4 and 12 weeks of treatment and no apparent benefit at the high dose. These preliminary results are in keeping with the in-vitro data, which demonstrated a biphasic effect of the drug (effective in reducing vascular permeability at very low doses and cessation of these beneficial effects at the higher doses, which are used clinically for other approved indications)."

Dr. Clift continued, "Based on these positive and encouraging results and the potential of lack of efficacy at the higher doses, both doses being present in this study, Ampio decided to conclude this study ahead of schedule and to proceed with the preparation of a consultation pack
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Atlanta-based Med Tech Company CardioMEMS Raises Additional Capital to Advance its CHAMPION Clinical Trial for its Wireless Sensor System for Heart Failure Monitoring
4. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
5. Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
6. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
7. Chay Enterprises Inc. Completes Merger With Repurposed Drug Developer Ampio Pharmaceuticals, Inc.
8. Ampio Pharmaceuticals, Inc. Retains Redwood Consultants, LLC to Assist in Shareholder Relations and Strategic Planning
9. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
10. Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer
11. Higher Education Leaders Receive TCWF Champions of Health Professions Diversity Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led by ... a premier and affordable laser tattoo removal experience with the ... focus is in providing high quality cosmetic services with cutting edge ... " Southern California has seen a dramatic ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... Connecticut waterways may be safer from biomedical waste, thanks ... program. CEDF, with loan-program partners, Connecticut ,s Department of Economic and Community ... loan to a West Haven company that stems improper disposal of ... , West ...
... 14 Hospira, Inc. (NYSE: ... medication delivery company, will expand its commitment to non-DEHP ... of non-DEHP intravenous (I.V.) administration sets. This effort reflects ... and reduced impact on the environment, and coincides with ...
Cached Medicine Technology:West Haven Firm Expands Biomedical Disposal Program with Community Economic Development Fund 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 2Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 3Hospira to Standardize Intravenous (I.V.) Administration Sets Portfolio to Non-DEHP 4
(Date:4/22/2014)... lung cancer are 70 years of age or older, ... not well represented in clinical trials. Therefore, the paucity ... evidence based clinical recommendations. , In 2010, the EORTC ... Group along with the International Society for Geriatric Oncology ... elderly patients with non-small cell lung cancer (NSCLC), and ...
(Date:4/22/2014)... to trauma, illness, alcohol or other drug abuse, these ... cells that can go awry and activate conditions such ... autism. , Until now, it has been unclear how ... developing brain. Past studies have shown that when an ... or she experiences some trauma or illness, her baby ...
(Date:4/22/2014)... (April 22, 2014) Cedars-Sinai stroke intervention researchers have ... and Stroke, part of the National Institutes of Health, ... multicenter Phase II clinical trial of an experimental drug ... used in combination with recombinant tissue plasminogen activator, or ... ischemic strokes shortly after onset. In laboratory rodent studies, ...
(Date:4/22/2014)... Based on results of a clinical trial ... Food and Drug Administration (FDA) approved a molecularly ... cancer that has progressed after standard chemotherapy has ... review was announced by the manufacturer, Lilly Oncology, ... name ramucirumab, it will be sold under the ...
(Date:4/22/2014)... of the University of Calgary,s Hotchkiss Brain Institute (HBI) ... cells as a means to restore connections after injury. ... key molecule that directly regulates nerve cell growth in ... the prestigious journal Nature Communications , with lead ... "We made the surprising discovery that a protein called ...
Breaking Medicine News(10 mins):Health News:EORTC and SIOG update expert opinion on management of elderly patients with NSCLC 2Health News:Life stressors trigger neurological disorders, researchers find 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:Scientists discover a new way to enhance nerve growth following injury 2
... BELLEVUE, Wash. and WASHINGTON, Oct. 4 Revolution,Health ... fastest growing health,properties, and drugstore.com (Nasdaq: DSCM ... and pharmacy products, today announced a major,agreement whereby ... the Revolution Health Network and manage advertising sales ...
... and Research,s (A*STAR) Institute of Molecular and Cell ... provide a more detailed understanding of how the ... albicans transforms into a serious and often life-threatening ... serious and potentially life-threatening infections in the mouth, ...
... FAIRFAX, Va., Oct. 4 SRA International, Inc.,(NYSE: ... and strategic consulting,services and solutions to federal government ... an enterprise-wide infrastructure,architecture for the Department of Justice ... Support Services-3 contract, has an,estimated value of $59 ...
... ,Tour to Insure, will Highlight Need to Reduce,Costs, Expand ... G.,Rendell will continue his campaign to reduce the costs ... with the passage of the,remainder of his "Prescription for ... bus tour. The five-day, nine-stop "Tour to Insure",will include ...
... operational,clinical and technological innovator in emergency medical services, ... ground, this time in the,way it hires the ... and around,Charlotte, N.C. While the nation,s emergency ... already trained in an academic setting,Medic is hiring ...
... Drive for Decision, CHARLESTON, S.C., Oct. 4 ... to introduce a proactive self-funding process to,secure the ... for the domestic shrimping industry. Beginning in January ... combination of federal government,assistance, voluntary industry contributions, foundation ...
Cached Medicine News:Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 2Health News:drugstore.com and Revolution Health Group Announce Breakthrough Deal 3Health News:How Candida albicans transforms from its normally benign form into life-threatening form 2Health News:Department of Justice Awards $59M Task Order to SRA 2Health News:Governor Rendell to Fight to 'Cover All Pennsylvanians' During Statewide Bus Tour 2Health News:Mecklenburg EMS Agency Launches Innovative Program to Pay Future EMT's While They Train 2Health News:Wild American Shrimp Board Agrees To Implement New Self-Funding Measures 2
Full Handle Laseredge Stab Blade Knife, 30 blade. Blade tip dimension: 10.5 mm x 1.9 mm x 3.4 mm....
19 Gauge. Reusable. Block of 4 each....
Set consist of two 27 gauge, stainless steel probes with blunt tips. Probes are 11.5 cm (4.5 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto th...
19 gauge x 8 mm with 15 cm high pressure extension tube preattached to a 10C ring control syringe. 3 per box....
Medicine Products: